Advertisement
SILO Forex Haberleri
Silo Pharma Exercises Option To License AD Therapeutic SPC-14 From Columbia University
Biopharmaceutical company Silo Pharma, Inc. (SILO) announced Wednesday that it has exercised its option to license Alzheimer's disease (AD) therapeutic SPC-14 from Columbia University, pursuant to a sponsored research and option agreement established in 2021.
RTTNews
|
520 gün önce
